Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.
Sikander AilawadhiRachael SextonSuzanne LentzschMuneer H AbidiPeter M VoorheesAdam David CohenEric M RohrenStephen B HeitnerKevin KellyNiklas J MacklerDavid M BaerAntje HoeringBrian DurieRobert Z OrlowskiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
This randomized trial did not support a benefit of fixed duration, twice weekly 56 mg/m2 dosing of carfilzomib over the 27 mg/m2 dose for the treatment of relapsed and/or refractory multiple myeloma. However, treatment to progression in earlier patient populations with high-dose carfilzomib using different schedules should still be considered as part of the standard of care.